Evidence map›Paper›PMID 26820970›Full record

ArticlePloS one2016

Analysis of Lymphocytic DNA Damage in Early Multiple Sclerosis by Automated Gamma-H2AX and 53BP1 Foci Detection: A Case Control Study.

Ludwig Rasche, Lisa Heiserich, Janina Ruth Behrens, Klaus Lenz, Catherina Pfuhl, Katharina Wakonig, René Markus Gieß, Erik Freitag, Caroline Eberle, Jens Wuerfel and 6 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Establishment ofFrontiers in public health · 2022
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Ludwig RascheNeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Lisa HeiserichMedipan GmbH, Berlin-Dahlewitz, Germany.
Janina Ruth BehrensNeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Klaus LenzDepartment of Medical Biometrics and Clinical Epidemiology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Catherina PfuhlNeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Katharina WakonigNeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany.
René Markus GießNeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Erik FreitagNeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Caroline EberleMedipan GmbH, Berlin-Dahlewitz, Germany.
Jens WuerfelNeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Jan DörrNeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Peter BauerMedipan GmbH, Berlin-Dahlewitz, Germany.
Judith Bellmann-StroblNeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Friedemann PaulNeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Dirk RoggenbuckMedipan GmbH, Berlin-Dahlewitz, Germany.
Klemens RuprechtClinical and Experimental Multiple Sclerosis Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Charité - Universitätsmedizin Berlin · DEMedipan (Germany) · DEBrandenburg University of Technology Cottbus-Senftenberg · DEUniversitätsmedizin Göttingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn response to DNA double-strand breaks, the histone protein H2AX becomes phosphorylated at its C-terminal serine 139 residue, referred to as γ-H2AX. Formation of γ-H2AX foci is associated with recruitment of p53-binding protein 1 (53BP1), a regulator of the cellular response to DNA double-strand breaks. γ-H2AX expression in peripheral blood mononuclear cells (PBMCs) was recently proposed as a diagnostic and disease activity marker for multiple sclerosis (MS).

objectiveTo evaluate the significance of γ-H2AX and 53BP1 foci in PBMCs as diagnostic and disease activity markers in patients with clinically isolated syndrome (CIS) and early relapsing-remitting MS (RRMS) using automated γ-H2AX and 53BP1 foci detection.

methodsImmunocytochemistry was performed on freshly isolated PBMCs of patients with CIS/early RRMS (n = 25) and healthy controls (n = 27) with γ-H2AX and 53BP1 specific antibodies. Nuclear γ-H2AX and 53BP1 foci were determined using a fully automated reading system, assessing the numbers of γ-H2AX and 53BP1 foci per total number of cells and the percentage of cells with foci. Patients underwent contrast enhanced 3 Tesla magnetic resonance imaging (MRI) and clinical examination including expanded disability status scale (EDSS) score. γ-H2AX and 53BP1 were also compared in previously frozen PBMCs of each 10 CIS/early RRMS patients with and without contrast enhancing lesions (CEL) and 10 healthy controls.

resultsThe median (range) number of γ-H2AX (0.04 [0-0.5]) and 53BP1 (0.005 [0-0.2]) foci per cell in freshly isolated PBMCs across all study participants was low and similar to previously reported values of healthy individuals. For both, γ-H2AX and 53BP1, the cellular focus number as well as the percentage of positive cells did not differ between patients with CIS/RRMS and healthy controls. γ-H2AX and 53BP1 levels neither correlated with number nor volume of T2-weighted lesions on MRI, nor with the EDSS. Although γ-H2AX, but not 53BP1, levels were higher in previously frozen PBMCs of patients with than without CEL, γ-H2AX values of both groups overlapped and γ-H2AX did not correlate with the number or volume of CEL.

conclusionγ-H2AX and 53BP1 foci do not seem to be promising diagnostic or disease activity biomarkers in patients with early MS. Lymphocytic DNA double-strand breaks are unlikely to play a major role in the pathophysiology of MS.

Indexed as

DNA DamageAdultBiomarkersCase-Control StudiesFemaleHistonesHumansIntracellular Signaling Peptides and ProteinsLymphocytesMaleMiddle AgedMultiple SclerosisTumor Suppressor p53-Binding Protein 1Young AdultBiomarkersH2AX protein, humanHistonesIntracellular Signaling Peptides and ProteinsTP53BP1 protein, humanTumor Suppressor p53-Binding Protein 1

Identifiers

PMID26820970
PMCPMC4731473
OpenAlexW2400919055

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.